Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Improvements in early detection and treatment have led to a growing prevalence of survivors
of cancer worldwide. Models of care fail to address adequately the breadth of physical …

Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Breast cancer is the most common global malignancy and the leading cause of cancer
deaths. Despite this, undergraduate and postgraduate exposure to breast cancer is limited …

Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …

Background Breast cancer still is a topic. This overview of the literature aimed to update the
current knowledge on quality of life in breast cancer patients. Methods A review of literature …

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …